Jiupai Capital

Wu Zhengyan, the firm's founder and chairman, holds controlling authority over investment committee decisions. The concentrated governance structure places deal approval and portfolio construction under his direct oversight, consistent with founder-led private equity firms in China's domestic market.

Jiupai Capital deploys capital from seed and start-up rounds through expansion, late-stage growth, PIPEs, and pre-IPO positions. The multi-stage mandate allows the firm to support portfolio companies across the full maturity cycle, though this breadth is unusual for a platform of its estimated size.

The firm concentrates on enterprise software, artificial intelligence and machine learning, healthcare services, industrial technology, and energy transition. These sectors align with China's policy-driven push toward technological self-reliance and domestic healthcare modernization.

Jiupai primarily executes direct equity investments across venture and buyout strategies. The firm has not publicly disclosed limited partner commitments to external funds, and its observed activity suggests a direct-investment orientation.

The firm's deal flow concentrates on mainland China, with sourcing anchored in Shenzhen, Beijing, and Shanghai. There is no disclosed international office network, and the portfolio reflects a domestic-first investment posture.

Jiupai has not publicly disclosed assets under management. Altss estimates the firm manages RMB 5-10 billion based on observed fund structures and deal volume, though this band should be treated as indicative pending direct confirmation from the firm.

There is no public record of a connected philanthropic foundation or impact-investment vehicle operating alongside Jiupai Capital. The firm's disclosed activities center exclusively on for-profit private equity.